282 related articles for article (PubMed ID: 23147993)
21. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
22. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.
Molldrem J; Dermime S; Parker K; Jiang YZ; Mavroudis D; Hensel N; Fukushima P; Barrett AJ
Blood; 1996 Oct; 88(7):2450-7. PubMed ID: 8839835
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer.
Lee HJ; Hong CY; Jin CJ; Kim MH; Lee YK; Nguyen-Pham TN; Lee H; Park BC; Chung IJ; Kim HJ; Lee JJ
Cell Mol Immunol; 2012 Mar; 9(2):175-83. PubMed ID: 22231555
[TBL] [Abstract][Full Text] [Related]
24. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
[TBL] [Abstract][Full Text] [Related]
25. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
26. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia.
Ochi T; Fujiwara H; Suemori K; Azuma T; Yakushijin Y; Hato T; Kuzushima K; Yasukawa M
Blood; 2009 Jan; 113(1):66-74. PubMed ID: 18820130
[TBL] [Abstract][Full Text] [Related]
27. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.
Torikai H; Akatsuka Y; Miyauchi H; Terakura S; Onizuka M; Tsujimura K; Miyamura K; Morishima Y; Kodera Y; Kuzushima K; Takahashi T
Bone Marrow Transplant; 2007 Jul; 40(2):165-74. PubMed ID: 17530010
[TBL] [Abstract][Full Text] [Related]
28. Targeting cathepsin G in myeloid leukemia.
Alatrash G
Oncoimmunology; 2013 Apr; 2(4):e23442. PubMed ID: 23734308
[TBL] [Abstract][Full Text] [Related]
29. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
He Y; Mao L; Lin Z; Deng Y; Tang Y; Jiang M; Li W; Jia Z; Wang J; Ni B; Wu Y
Mol Immunol; 2008 May; 45(9):2455-64. PubMed ID: 18295890
[TBL] [Abstract][Full Text] [Related]
30. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
[TBL] [Abstract][Full Text] [Related]
31. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
[TBL] [Abstract][Full Text] [Related]
32. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
33. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.
St John LS; Wan L; He H; Garber HR; Clise-Dwyer K; Alatrash G; Rezvani K; Shpall EJ; Bollard CM; Ma Q; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):995-1001. PubMed ID: 27378343
[TBL] [Abstract][Full Text] [Related]
34. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
[TBL] [Abstract][Full Text] [Related]
35. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.
Ochsenreither S; Majeti R; Schmitt T; Stirewalt D; Keilholz U; Loeb KR; Wood B; Choi YE; Bleakley M; Warren EH; Hudecek M; Akatsuka Y; Weissman IL; Greenberg PD
Blood; 2012 Jun; 119(23):5492-501. PubMed ID: 22529286
[TBL] [Abstract][Full Text] [Related]
37. Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia.
Lu S; Tallis E; Ding X; Li D; Cox K; You MJ; St John L; Alatrash G; Ma Q; Molldrem JJ
Cytotherapy; 2021 Sep; 23(9):793-798. PubMed ID: 34215503
[TBL] [Abstract][Full Text] [Related]
38. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
39. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
40. The CD68 protein as a potential target for leukaemia-reactive CTL.
Sadovnikova E; Parovichnikova EN; Savchenko VG; Zabotina T; Stauss HJ
Leukemia; 2002 Oct; 16(10):2019-26. PubMed ID: 12357353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
